Drug Profile
Fibrin patch - Ethicon/Omrix Biopharmaceuticals
Alternative Names: Evarrest; Fibrin pad; Fibrin sealant patchLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Ethicon; OMRIX Biopharmaceuticals
- Class Antihaemorrhagics; Blood coagulation factors; Blood proteins; Serine endopeptidases
- Mechanism of Action Fibrin stimulants; Thrombin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Surgical blood loss
Most Recent Events
- 27 Aug 2019 Phase III development is ongoing in Australia, Japan, New Zealand, USA and United Kingdom (Ethicon pipeline, August 2019)
- 05 Mar 2016 Phase-III clinical trials in Surgical blood loss (In adolescents, In children, In infants, In neonates) in England before March 2016 (Perilesional)
- 05 Mar 2016 Efficacy data from a phase III trial in Surgical blood loss released by Ethicon